Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cytovance and Precision Biologics Announce Extension of Manufacturing Agreement

Published: Saturday, March 29, 2014
Last Updated: Saturday, March 29, 2014
Bookmark and Share
Extension of cGMP manufacturing agreement for NEO-102 drug product.

Cytovance Biologics, Inc. is extending its manufacturing agreement with Precision Biologics, Inc., a Texas-based clinical stage biopharmaceutical company.

Precision Biologics is advancing its clinical trials with its leading monoclonal antibody candidate - referred to as Ensituximab or NEO-102 - which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers.

Precision has contracted Cytovance Biologics as its CMO to provide technology transfer and additional cGMP manufacturing services of NEO-102 in support of its ongoing Phase 2 clinical trials.

“With this agreement, Precision Biologics is strengthening its longstanding and growing relationship with the scientific professionals of Cytovance,” said Dr. Albine Martin, COO of Precision Biologics, Inc. “Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers.”

“Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics, Inc.

Head continued, “We are proud to be an established partner with Precision Biologics and support them in their expanded clinical trial program.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cytovance Biologics Selected for GMP Manufacture of AM0010
Provides drug product for Phase I trials.
Tuesday, July 01, 2014
Cytovance Biologics and Pamlico Biopharma Announce Agreement
Development and cGMP manufacturing agreement to advance the treatment of Streptococcus pneumoniae infections.
Friday, February 21, 2014
Cytovance® Biologics to Expand Production Capabilities in 2013
Cytovance® Biologics, Inc. announced that it will expand its current mammalian production capabilities to include a 1,000L SUB bioreactor, a 5,000L stainless steel bioreactor and an automated fill/finish line.
Wednesday, January 30, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!